Literature DB >> 2426862

Proteins of lymphocytic choriomeningitis virus: antigenic topography of the viral glycoproteins.

B S Parekh, M J Buchmeier.   

Abstract

Topographical relationships among antigenic sites on the envelope glycoproteins of lymphocytic choriomeningitis virus (LCMV) were established using a panel of monoclonal antibodies (MAb) directed against viral GP-1 and GP-2. Purified MAb were radioiodinated and used as probes in a solid phase competitive binding assay. Epitopes on LCMV GP-1 were found to cluster in four antigenic sites. Five neutralizing MAb raised by immunization with the WE strain of LCMV reacted with a single topographic site, termed GP-1A, which was present on four strains of LCMV examined in this study. A second site, GP-1B, was characterized by two MAb which partially competed with one another and with a subset of neutralizing antibodies. This site appeared to be close to site A and was found to be nonneutralizing. The third site, GP-1C, contained sequential epitopes and was also nonneutralizing. Antibodies binding to site B enhanced the binding of MAb at site C, presumably through a conformational change. In addition to the common neutralizing site A, LCMV Armstrong strain (LCMV-Arm) GP-1 contained a second topographically related neutralizing site, GP-1D, which was specific for LCMV-Arm, absent in WE, and appeared to be the major immunogenic epitope on GP-1 of this virus. Analysis of MAb binding to LCMV GP-2 demonstrated the presence of three overlapping binding sites. GP-2A was defined by two antibodies while GP-2B and C represented binding sites of one antibody each. Guinea pigs primed with LCMV-Arm and challenged with LCMV-WE developed a significant immune response which was directed toward the common major neutralizing site, GP-1A, but had poor responses to the LCMV-Arm specific neutralizing site GP-1D. Immune sera contained antibody to site GP-1B but lacked detectable antibody to GP-1C.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2426862     DOI: 10.1016/0042-6822(86)90020-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  41 in total

1.  Viral persistence in vivo through selection of neutralizing antibody-escape variants.

Authors:  A Ciurea; P Klenerman; L Hunziker; E Horvath; B M Senn; A F Ochsenbein; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP.

Authors:  Magali E Droniou-Bonzom; Therese Reignier; Jill E Oldenburg; Alex U Cox; Colin M Exline; Jessica Y Rathbun; Paula M Cannon
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

3.  Virus-specific, CD8+ major histocompatibility complex class I-restricted cytotoxic T lymphocytes in lymphocytic choriomeningitis virus-infected beta2-microglobulin-deficient mice.

Authors:  D G Quinn; A J Zajac; C E Hioe; J A Frelinger
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  O Mannosylation of alpha-dystroglycan is essential for lymphocytic choriomeningitis virus receptor function.

Authors:  Mauro Imperiali; Claudio Thoma; Ernesto Pavoni; Andrea Brancaccio; Nico Callewaert; Annette Oxenius
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Characterization of the interaction of lassa fever virus with its cellular receptor alpha-dystroglycan.

Authors:  Stefan Kunz; Jillian M Rojek; Mar Perez; Christina F Spiropoulou; Michael B A Oldstone
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins.

Authors:  Bruno Eschli; Katharina Quirin; Alexander Wepf; Jacqueline Weber; Rolf Zinkernagel; Hans Hengartner
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

7.  Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection.

Authors:  K E Wright; M J Buchmeier
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

8.  Lassa virus glycoproteins: antigenic and immunogenic properties of synthetic peptides to GP1.

Authors:  A G Krasko; A B Moshnikova; A T Kozhich; L D Tchikin; V T Ivanov; A S Vladyko; I S Lukashevich
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

Review 9.  Progress towards recombinant anti-infective antibodies.

Authors:  Jennifer C Pai; Jamie N Sutherland; Jennifer A Maynard
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2009-01

10.  LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration.

Authors:  I S Lukashevich; J D Rodas; I I Tikhonov; J C Zapata; Y Yang; M Djavani; M S Salvato
Journal:  Arch Virol       Date:  2004-08-30       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.